Sage puts pieces in place for growth as Greene, an architect of Alnylam, becomes CEO

Alnylam and Millennium alum Barry Greene has joined Sage as CEO, freeing up Jeff Jonas to bolster the neurology company’s pipeline.

Jonas, who becomes chief innovation officer and chair of the board of directors’ science and technology forum, joined  Sage Therapeutics Inc. (NASDAQ:SAGE) as CEO in 2013. Jonas led the company to its first FDA approval, for Zulresso brexanolone, the first drug specifically indicated to treat postpartum depression...